Please login to the form below

Not currently logged in
Email:
Password:

Actinium appoints director of clinical operations

Gregory Bergonio brings experience from Novartis

New York, US-based Actinium Pharmaceuticals has appointed Gregory Bergonio as director of clinical operations, with particular responsibility for its Actimab-A phase II clinical trial programme.

Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.

Prior to this, Bergonio held a number of clinical research management positions at Bausch & Lomb, OSI Eyetech, Forest Laboratories, i3 Research and Kern McNeil.

Sandesh Seth, Actinium's executive chairman, said: “We are very excited to welcome Greg to the clinical development team at Actinium.

“Greg's joining comes at an ideal time given our increased development efforts as a result of the Actimab-A phase II trial and Iomab-B pivotal phase III SIERRA trial.

“Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our current and planned clinical development efforts.”

5th January 2017

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...